Cannabix Technologies (CSE:BLO) announced it filed for a Patent Cooperation Treaty (PCT) application “Device and Method for Detection of Cannabis and Other Controlled Substances Using FAIMS.”
As quoted in the press release:
This PCT covers intellectual property related to earlier versions of the Cannabix Marijuana Breathalyzer. Under its relationship with the University of Florida (“the University”), the Company has entered into a second license agreement with the University for PCT application CA2017/000042. The agreement provides Cannabix exclusive worldwide rights in the area of breath analysis of controlled substances. Cannabix is developing an innovative FAIMS (field asymmetric waveform ion mobility spectrometry) based instrument for the detection of ∆9-tetrahydrocannabinol in human breath.
In recent months the Company has been characterizing its Beta 3.0 Cannabix Marijuana Breathalyzer prototype performance measures both independently and coupled to a mass spectrometer (MS), in preparation for expanded field testing.
Click here to read the full press release.
The post Cannabix Technologies Applies for Cannabis Detection Patent appeared first on Investing News Network.
